Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilebesiran as add-on therapy in high CV risk patients with uncontrolled hypertension
NCT06272487Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Countries
- 6
01
Overview
A Phase 2 trial of zilebesiran in hypertension (HTN), sponsored by Alnylam Pharmaceuticals. Started Feb 2024; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06272487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06272487.